MedTrace Logo

COVID-19 on Placental Gene Expression and Pathology

NCT04585945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2026-02-27

No results posted yet for this study

Summary

Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnormal placental pathology or altered metabolism is associated with severity of symptoms (specifically pneumonia, or need for admission), gestational age at onset, and/or placenta efficiency. Histological and gene expression analysis of the placental post-delivery will determine if COVID-19 alters overall placental structure, vascularization, and/or the transcriptome.

Conditions

Interventions

DIAGNOSTIC_TEST

Positive for SARS-CoV-2 infection

Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.

Sponsors & Collaborators

  • Prisma Health-Upstate

    lead OTHER

Principal Investigators

  • Jessica Britt, PhD · Prisma Health-Upstate

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2021-04-21
Completion
2022-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04585945 on ClinicalTrials.gov